无并购,不巨头:中国医药迈向 MNC 的必经之路

药智网
Sep 16

导读:并购给行业带来的重构价值为何又如此重要?如果说一笔又一笔的License out是中国 创新药 走向世界舞台的标志,那么下一步大型药企对于优质资产的并购趋势,就将成为中国制药企业迈向MNC的关键转折。2024年9月,中国证监会发布了“并购六条”,显著推动了医药领域的并购活动,为 生物医药 和创新药物领域的市场重组打下了基础。2025年7月, 中国生物制药 宣布将以10亿美元的估值收购上海礼新...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10